ArticleHarm reduction journal2025
Gender-based differences in harm reduction practices among people who use drugs in Rhode island: a latent class analysis.
Article in Harm reduction journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Identification of distinct stimulant use trajectories and patterns of overdose.Addictive behaviors reports · 2026Article
- Sociodemographic, behavioral, and geospatial factors associated with syringe services program use in San Francisco, California.Drug and alcohol dependence · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundPrevious research has documented differing drug use patterns and risk behaviors by gender identity and sex at birth, although variations in harm reduction practices by these characteristics have not yet been fully assessed.
methodsWe utilized data from the Rhode Island Prescription and Illicit Drug Study (RAPIDS), which enrolled adults who used drugs from 2020 to 2023. Participants were analyzed based on gender identity: men, women, and other (including those identifying as non-binary or something else). Participants reported which harm reduction practices (e.g., use fentanyl test strips, keep naloxone nearby) they typically engaged in to avoid accidental overdose. Latent class analysis (LCA) was used to identify subgroups of harm reduction practice typologies, and a correlation matrix was generated to understand dyads of typical self-reported harm reduction practices.
resultsAmong 503 eligible participants, 64% were men, 34% were women, and 2% were non-binary or something else (n = 9). Harm reduction practices were comparable between men and women, although men were less likely to keep naloxone nearby (p = 0.02). LCA identified three subgroups of harm reduction practice typologies (no/low, moderate, and high utilization). Group membership in latent classes did not vary by gender identity. However, those belonging to the no/low utilization subgroup were significantly more likely to have ever been incarcerated (p = 0.03) and to be single (p < 0.01). Those belonging to the high utilization group were significantly more likely to have ever witnessed an overdose, performed rescue breathing, and administered naloxone (all p < 0.001). Correlations showed several pairwise relationships, with 'use fentanyl test strips' and 'keeping naloxone nearby' being positively and significantly correlated (r = 0.33, p < 0.05).
conclusionsWe found that harm reduction practices and group membership in latent classes were largely comparable between men and women; however, men who use drugs are significantly less likely to keep naloxone nearby. Gender-attentive strategies to increase naloxone carriage and usage among men and enhanced outreach to persons characterized by no or low harm reduction practice utilization, including people who are single and those with a history of incarceration, may be warranted to mitigate overdose risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.